It May Be Time to Sell Shares of Celesio (ETR:CLS1) as Independent Research GmbH Has Downgraded The Company

Share

Celesio (ETR:CLS1) Receives a Downgrade

In analysts note distributed to Clients on Thursday morning, Independent Research GmbH downgraded their rating for shares of Celesio (ETR:CLS1) to a “Sell” and they now have a EUR 22.99 PT on the stock. Independent Research GmbH’s PT would suggest a possible downside of -7.93% from the last close price of Celesio (ETR:CLS1).

From a total of 2 analysts covering Celesio (ETR:CLS1) stock, 0 rate it a ”Buy”, 2 a “Sell”, and 0 a ”Hold”. This means that 0 of the ratings are positive. The highest target price is €23 while the lowest target price is €22.99. The mean of all analyst targets is €23 with a -8.04% below today’s (€25.01) stock price. Celesio was the topic of 2 analyst reports since August 11, 2015 according to the firm StockzIntelligence Inc. Landesbank downgraded shares on August 14 to “Sell” rating.

The stock increased 0.04% or EUR 0.01 on December 2, striking EUR 25.01. Approximately 68,812 shares of stock traded hands. Celesio AG (ETR:CLS1) has risen 6.00% since November 3, 2015 and is uptrending. It has outperformed by 6.20% the S&P500.

 It May Be Time to Sell Shares of Celesio (ETR:CLS1) as Independent Research GmbH Has Downgraded The Company

Celesio AG is a Germany-based trading firm and well-known provider of logistics and services in the pharmaceutical and healthcare sector. The company has a market cap of 5.08 billion EUR. It operates through two business divisions, namely Patient and Consumer Solutions, as well as Pharmacy Solutions. It has 16.72 P/E ratio. The Patient and Consumer Solutions division is aimed at patients and consumers, and covers the entire logistics chain, from purchasing merchandise through to selling to end consumers.

COMMENTS: